New resource available view now
POTOMAC, MARYLAND – February 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease.
POTOMAC, MARYLAND – January 22, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (“AI”) to develop innovative treatments for Alzheimer’s disease, today announced the addition of Integrative Clinical Trials,
Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities
POTOMAC, MARYLAND – January 6, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer’s Drug Development
New Patent Expands IGC Pharma’s Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer’s Disease
POTOMAC, MARYLAND – October XX, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease,
POTOMAC, MARYLAND – December 15, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for
POTOMAC, MD December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease, today
POTOMAC, MARYLAND – December 09, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for